^
    Back
    Association details:
    Biomarker:CCL11 overexpression
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:LucaVax (tertomotide) (Telomerase inhibitor, Viral replication inhibitor, HBsAg release inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASCO 2021
    Title:

    KG 4/2015: A randomized, controlled, multicenter, open-label phase III clinical trial of GV1001 with gemcitabine/capecitabine in previous untreated, eotaxin-high patients with advanced pancreatic ductal adenocarcinoma.

    Published date:
    05/19/2021
    Excerpt:
    148 pts randomly assigned to G/C/GV (n = 75; all eotaxine-high)...Median OS was significantly improved in the G/C/GV group with 11.3m...Also, median TTP was significantly improved in the G/C/GV group….G/C/GV treatments significantly extend OS and TTP in advanced PDA than G/C...GV1001 should be considered as one of the options in PDA pts with high serum eotaxin levels.
    Secondary therapy:
    gemcitabine + capecitabine
    DOI:
    10.1200/JCO.2021.39.15_suppl.4020
    Trial ID:
    KG 4/2015